NeuroCores, Inc.
201 Washington Street,
#2600. Boston,
MA 02108

About Us

Our Vision

Provide hope where none existed before

Our Mission

Develop plasmalogen derivatives that transform the lives of patients with rare pediatric neurological disorders and neurodegenerative diseases


Dr. T. Fujino, MD PhD, Founder

Professor Emeritus, Kyushu University in Japan

CEO, Rheology Functional Food Research Institute Co.& Fujino Brain Research Inc.

Founder of Plasmalogen Research Association & BOOCS Science Inc.

Eunhee Ohgami, PhD, CEO

She was previously the CSO at a prestigious Japanese medical group for over 12 years and the COO at a biotech start-up developing Dementia Treatments.

Global head of clinical development from 2015 to 2022, helping global biotech companies enter the Japanese and US market.

700+ clinical study experience in the CNS area.

Christopher Aleong, Chief Strategy Officer

Christopher has over twenty-five years of global experience in the pharma and biotech sectors. In past years with Bayer, Abbott and Sanofi, he held executive roles in general management, sales & marketing, commercial operations, finance and human resources.

Executive expertise in commercialization of innovation, strategic and operational reviews, market analysis, business development assessments, organizational transformations and growth, customer engagement and business partnerships in developed and emerging markets.

Bruce Smith, CFO

Top-performing senior financial executive with an entrepreneurial spirit and strong record of providing people, processes, and systems necessary for rapid growth and global expansion in fast-paced, competitive industries.

Proven ability to reduce costs, improve efficiencies, build robust relationships with other departments, attract and develop top talent, manage internal and external resources, and improve accounting policies and procedures. Skilled at leveraging systems to improve business effectiveness.

Scientific Advisors

Kelly Austin, PhD, PPM

She is a regulatory specialist, especially in orphan and rare disease drug development.

She has supported 300+ FDA and 100+ EMA Orphan drug submissions and 100+ Fast Track, Breakthrough, and RMAT submissions.

Deborah Hartman, PhD

Scientist and senior leader with international experience in pharmaceutical research and a proven track record of advancing drug candidates through discovery and early clinical development in CNS areas.

Previously, she was Chief Scientific Officer in 3 medium biotech companies and Vice President and global program leader of a multinational pharmaceutical company.

Deborah Lee, MD PhD

She is an MD specializing in Pediatric neurology, peripheral neuropathies, and Alzheimer’s disease. She has extensive drug development experience as a senior medical director at several multinational pharmaceutical companies.

Scientific Advisory Board

Shiro Mawatari MD, Ph.D.
M.D.Ph.D. (Internal Medicine and Neurology Specialist) Director, IRFF

At IRFF, he has developed new measurement and extraction techniques for lipids and other substances, and is engaged in the extraction and development of functional substances from food materials using these techniques. As part of these efforts, he has. developed a method for mass extraction and simple measurement of plasmalogen and discovered new polyphenols.

  • 1971 D., Graduate School of Medicine, Kyushu Univ. 1972 Research Assistant, Faculty of Medicine, Kyushu University
  • 1972 Fellow, University of Pennsylvania School of Medicine
    (Biochemical studies of erythrocyte membranes in dystrophy)
  • 1973 Fellow, Columbia University, Institute of Neurological Diseases
    (biochemical studies of erythrocyte membranes in dystrophy)
  • 1976 Associate Professor, Kyushu Institute of Technology
  • 1981 Deputy Director, National Sanatorium Chikugo Hospital
  • 1989 Director, NTT Fukuoka Headquarters or Health Management Center
  • 1994 Professor, Faculty of Human Environment, Fukuoka Women’s University
  • 2005 Director, IRFF
Shamim Hossain Ph.D.
IRFF Director of Basic Research

His experience in molecular biology has led him to study neuroinflammation, memory dysfunction, diabetes, pathogenic susceptibility, cancer, and more related to aging.

  • 2003 M.S. Rajshahi University, Bangladesh
  • 2009 Ph.D., Chiba Univ. Graduate School of Medicine (Research on novel proto-oncogenes in tumorigenesis)
  • 2003 Lecturer, Faculty of Pharmacy, Rajshahi Univ.
  • 2009 Chiba Cancer Center Research Department Growth Factors in Cancer Development
  • 2012 Associate Professor, Chiba Cancer Center
  • 2016 Kyushu Univ. Medical Research Aging and Pathological Repair
    Associate Professor/Principal Investigator -Age-related physiological changes. -neuroinflammation, memory impairment, intestinal bacterial sac symbiosis, metabolic syndrome, immune dysfunction (NK cells, macrophages immune dysfunction (NK cells, macrophages), etc.
Tatsuo Okauchi Ph.D.
Graduate School of Kyushu Institute of Technology Associate Professor, Department of Materials Science and Engineering, Faculty of Engineering

Ph.D. in Science, The University of Tokyo Dr. of Tokyo University.

  • 1992-1995 Synthesis Researcher, Exploratory
    Research Dept. 5, Eisai Tsukuba Research Laboratories (Development of Novel Anticancer Drugs)
  • 1995-1999 Research Assistant, Faculty of Engineering, Kyushu Institute of Technology (Development of catalytic asymmetric synthetic reactions using optically active phosphorus ligands)
  • 1999-2002 Lecturer,
    Faculty of Engineering, Kyushu Institute of Technology (Development of organic synthetic reactions using metal- olefin complexes)
  • 2002-2008 Associate Professor, Faculty of Engineering, Kyushu Institute of Technology (Associate Professor, Faculty of Engineering, Kyushu Institute of Technology (Synthesis of bioactive compounds with phosphorus atom)
  • 2008– Associate Professor,
    Faculty of Engineering, Kyushu Institute of Technology Associate Professor, Faculty of Engineering, Kyushu Institute of Technology
    (Development of new synthetic methods for
    phosphate esters; Synthesis of bioactive compounds with phosphorus atoms) [incumbent].
Masanori Honjo Ph.D.
Kyushu University Graduate School of Medicine Associate Professor of Age-Related Pathology
  • 1997 Japan Science and Technology Corp. (Research on cell organellogenesis)
  • 1998 Ph.D. of Science
  • 2001 Max-Planck-Institute of Molecular Cell Biology and Genetics
  • 2003 Assistant Professor, Graduate School of Systems Life Science, Kyushu University (Research on peroxisome biosynthesis)
  • 2008 Project Associate Professor, Graduate School of Science, Kyushu University (Research on cell fate determination and its disruption and its disruption)
  • 2011 Associate Professor, Graduate School of Science, Kyushu University (Research on regulation of ether phospholipid biosynthesis)
  • 2015 Specially Appointed Associate Professor, Institute for Defensive Medical Sciences, Kyushu University
  • 2019 Director of Basic Research, IRFF (Research on novel physiological functions of ether phospholipids)
  • 2020 Associate Professor, Graduate School of Medicine, Kyushu University
    (Research on homeostasis mechanisms and novel physiological functions of ether phospholipids)

How We Work

Everything we do at NeuroCores is based on:

Putting patients first

being a great place to work

honoring our core values

We are committed to conducting our business with integrity and the pursuit of excellence. Our Management Team and our Board of Directors are committed to honesty and compliance with all laws, rules, and regulations that apply to our business.

Our Core Values

Compassion & Care

We are driven by a deep compassion for children and their families affected by devastating rare pediatric neurological conditions. Providing hope through transformative therapies is at the heart of our mission.

Scientific Excellence

We are relentless in our pursuit of scientific excellence and innovation. Our team of world-class researchers leverage the latest advances in plasmalogen biology, neuroscience and biotechnology. We are committed to rigorous research, data-driven evidence and upholding the highest ethical standards.

Determination to Persevere

Developing breakthrough treatments for complex neurological disorders and neurodegenerative diseases require determination and the courage to persevere through immense challenges. We embrace this journey with resilience, passion and an unwavering commitment to our mission.

Integrity and Accountability

Integrity is paramount in everything we do. We hold ourselves accountable to the highest principles of integrity, transparency and responsible conduct. Our stakeholders’ trust is sacred, and we strive to honor it every day.